Page last updated: 2024-08-23

idarubicin and Atypical Chronic Myeloid Leukemia

idarubicin has been researched along with Atypical Chronic Myeloid Leukemia in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (75.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boissel, N; Cluzeau, T; Devillier, R; Dombret, H; Kiladjian, JJ; Lengline, E; Raffoux, E; Rey, J; Robin, M; Ronchetti, AM; Sebert, M; Vey, N	1
Bergamaschi, G; Carella, AM; Cazzola, M; Ferrero, R; Podestá, M; Pollicardo, N; Pungolino, E; Raffo, MR; Rosti, V; Saglio, G	1
Benvenuto, F; Carella, AM; Ferrero, R; Figari, O; Frassoni, F; Giordano, D; Podestà, M; Pollicardo, N; Pungolino, E; Raffo, MR	1
Carella, AM; Celesti, L; Corsetti, MT; Dejana, A; Frassoni, F; Lerma, E; Panagiotis, Z	1

Trials

1 trial(s) available for idarubicin and Atypical Chronic Myeloid Leukemia

Article	Year
Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis. Leukemia, 1994, Volume: 8, Issue:1 Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged	1994

Article

Year

Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis.

Leukemia, 1994, Volume: 8, Issue:1

Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged

1994

Other Studies

3 other study(ies) available for idarubicin and Atypical Chronic Myeloid Leukemia

Article	Year
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. British journal of haematology, 2016, Volume: 172, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Treatment Outcome	2016
Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. Stem cells (Dayton, Ohio), 1993, Volume: 11 Suppl 3 Topics: Adult; Blast Crisis; Bone Marrow Transplantation; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged	1993
Effective mobilization of Philadelphia-chromosome-negative cells in chronic myelogenous leukaemia patients using a less intensive regimen. British journal of haematology, 1998, Volume: 100, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Pilot Projects	1998